Oncotarget

Research Papers:

Systematic review of CYFRA 21-1 as a prognostic indicator and its predictive correlation with clinicopathological features in Non-small Cell Lung Cancer: A meta-analysis

Zipu Yu, Guofei Zhang, Maoying Yang, Sai Zhang, Baiqin Zhao, Gang Shen and Ying Chai _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:4043-4050. https://doi.org/10.18632/oncotarget.14022

Metrics: PDF 2077 views  |   HTML 3691 views  |   ?  


Abstract

Zipu Yu1,*, Guofei Zhang1,*, Maoying Yang1, Sai Zhang1, Baiqin Zhao1, Gang Shen1, and Ying Chai1

1 Department of Thoracic Surgery, 2nd Affiliated Hospital, Zhejiang University, Hangzhou, China

* These authors have contributed equally to this work

Correspondence to:

Ying Chai, email:

Keywords: Cytokeratin 19 fragment (CYFRA 21-1); Non-small Cell Lung Cancer(NSCLC); 2-year overall survival; clinicopathological features

Received: September 12, 2016 Accepted: December 02, 2016 Published: December 19, 2016

Abstract

AIM: To evaluate the value of Cytokeratin 19 fragment for its survival prognostic indicator and predictive correlation with clinicopathological features in Non-small Cell Lung Cancer.

METHODS: Eligible studies or databases for articles were retrieved via search systematically. Pooled effect was calculated to evaluate the association between Cytokeratin 19 fragment level and long-term overall survival, as well as the tumor clinicopathological features in Non-small Cell Lung Cancer patients. A fixed-effects or random-effects model was used to calculate the Pooled risk ratios (RRs) and corresponding 95 % confidence intervals (CIs).

RESULTS: Six studies were up to the selection criteria. This meta-analysis indicated that Cytokeratin 19 fragment high level expression correlated with lower 2-year overall survival (RR =0.47; 95%CI: 0.28-0.79), higher Tumor Node Metastasis stage (II+III+IV) (RR =1.43; 95%CI: 1.15-1.76) in Non-small Cell Lung Cancer. The pooled RR estimates indicated that there is no statistical significance of Cytokeratin 19 fragment level expression in the advanced Non-small Cell Lung Cancer (IIIB+IV) (RR =1.43, 95% CI: 0.85-2.43).

CONCLUSION: Cytokeratin 19 fragment is a negative prognosis indicator and its high level expression indicates higher Tumor Node Metastasis pathological stage (II+III+IV) in Non-small Cell Lung Cancer. In advanced Non-small Cell Lung Cancer, the level of serum Cytokeratin 19 fragment appears to provide more prognostic information than it does for clinical Tumor Node Metastasis stage information. Further studies are required to confirm our results.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14022